(PSYCHIATRIC TIMES) - MedPage Today Action Points
SAN DIEGO, Calif., Oct. 30 -- Strattera (atomoxetine) given to children with attention deficit hyperactivity disorder does not appear to stunt growth over the long term, according to a lengthy study.
Height, weight and body mass index (BMI) percentiles dropped initially with Strattera treatment but returned to pretreatment levels after three years of continual therapy, said Thomas J. Spencer, M.D., of Massachusetts General Hospital and Harvard Medical School, and colleagues, at the American Academy of Child and Adolescent Psychiatry meeting here.
"In many patients, the disorder persists through adolescence into adulthood and therefore may require chronic treatment," Dr. Spencer reported at a poster session. "Few studies have examined the effect of long-term pharmacological treatments for ADHD on growth, as most long-term trials have lasted only one to two years."
For full article, please visit: